Energy balance
Tirzepatide treatment (5-15 mg weekly) significantly reduces serum uric acid (SUA) levels in adults with obesity or overweight, with weight reduction explaining 72.7% of this effect.
If you have obesity or overweight and are concerned about gout or high uric acid, tirzepatide (a once-weekly injection) can significantly lower your uric acid levels. Most of this benefit comes from the weight loss it causes, but it may also have direct effects. This makes it a potentially useful tool for managing gout risk in people with obesity, in addition to helping with weight loss.
Treatment with all dose groups of tirzepatide was associated with significant reductions of SUA at each time point, compared to placebo... Mediation analysis suggested that weight reduction explained 72.7% of SUA reduction.
Why this rating
Post-hoc analysis of a large, randomized, placebo-controlled trial (SURMOUNT-1) with 2539 participants.
Source
Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial
Naveed Sattar et al. · Annals of the Rheumatic Diseases · 2025
DOI 10.1016/j.ard.2025.10.009
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →